Brief: Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
20/03/2025 20:51
March 20 (Reuters) - Allurion Technologies Inc ALUR.N: ALLURION ANNOUNCES INITIAL RESULTS ON THE COMBINATION OF THE ALLURION PROGRAM WITH LOW-DOSE GLP-1 THERAPY TO OPTIMIZE MUSCLE MASS AND GLP-1 ADHERENCE ALLURION TECHNOLOGIES INC - AVERAGE TOTAL WEIGHT LOSS OF 20% WITH 15% INCREASE IN LEAN BODY MASS AFTER 8 MONTHS OF COMBINED THERAPY Source text: ID:nBw5P2Gb5a Further company coverage: ALUR.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allurion Technologies
See all newsBrief: Allurion Technologies Inc - Sees Growing Demand From Patients Discontinuing Glp-1 Therapy
Brief: Allurion Intends To Appeal NYSE Notice Of Delisting, Execute Plan To Regain Compliance, And Expects To Continue Trading On NYSE
Brief: NYSE To Commence Delisting Proceedings Against Allurion Technologies, Inc.
Allurion rises on plan to offer discounted weight-loss drug Mounjaro in Argentina
Allurion rises after strong weight-loss data from combination therapy